Microfluidics Market

The microfluidics market is projected to reach USD 37.2 billion by 2030 from USD 24.96 billion in 2025, at a CAGR of 8.3% during the forecast period. This growth is fueled by the technology’s ability to deliver fast, accurate results, improve the portability of medical devices, and offer quick returns on investment, making it highly attractive for healthcare and life science applications. Microfluidics enables compact, cost-effective, and efficient testing systems that support the rise of point-of-care diagnostics and personalized medicine. Advances in digital and droplet microfluidics, 3D printing, and AI integration are further expanding its potential across research and clinical use. However, the slow and complex regulatory approval process for incorporating microfluidics into existing medical workflows continues to challenge market growth.

The microfluidics field still faces hurdles that limit widespread use. PDMS remains popular due to its flexibility and transparency, but it is challenging to fabricate, prone to sealing issues, and incompatible with certain chemicals, prompting researchers to explore alternative materials such as thermoplastics, polycarbonate, and 3D-printed designs. Paper-based systems show promise but need more reliability and scalability. Many devices still rely on external instruments, which reduces portability and cost efficiency, while limited programmability makes each chip task-specific.

To know about the assumptions considered for the study download the pdf brochure

Emerging trends in the microfluidics industry are driving progress in several sectors. The shift from rigid silicon chips to flexible polymer and paper-based devices has made testing cheaper, faster, and more portable—perfect for point-of-care and wearable applications. At the same time, digital and droplet microfluidics are enabling precise, high-throughput control of tiny fluid droplets, driving breakthroughs in single-cell and drug screening research. 3D printing is making it easier to prototype and customize chips quickly, while AI integration is helping analyze massive datasets and automate experiments. Together, these trends are redefining how science and healthcare operate—making microfluidics smarter, more accessible, and central to the next wave of innovation.

Some of the key players in the microfluidics market are Abbott laboratories (US), Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD (US), Bio-Rad laboratories, Inc. (US), Danaher Corporation (US), Illumina Inc. (US) Parker Hannifin Corporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), Idex Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd. (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK), and Elveflow (France).

Danaher Corporation (US):  Danaher Corporation is a prominent player in the microfluidics sector and a leader in science and technology worldwide. The company has a presence in Europe, Asia Pacific, and North America. In 2023, the firm expanded its product selling across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The firm offers diagnostics and medical equipment associated with microfluidics through its life sciences and diagnostics segment. Its product portfolio comprises microfluidic dispensers, diagnostic testing systems, and lab analytics tools. The firm engages in strategic acquisitions to enhance its global presence.
 
Illumina, Inc. (US): Illumina is a significant player in the microfluidics market. It manufactures and sells life science tools, kits, and reagents. The firm offers microfluidics-based equipment through its Core Illumina segment. The firm has a presence in Africa, Asia Pacific, Central America, Europe, the Middle East, North America, and South America. The products offered by the country include microfluidic-based sequencing solutions such as HiSeq, MiSeq, NextSeq500, NovaSeq 6000, iScan System, MiniSeq Systems, NeoPrep Library Prep Systems, and PhiX Control v3. In October 2024, Illumina, Inc. (US) launched MiSeq i100 Series, which allows sequencing to occur on the same day. The product is cheaper and user-friendly, especially for labs that have limited NGS knowledge.

Biomerieux (France): Biomerieux is making significant advancements in point-of-care devices and gene test kits. The firm has a presence in 45 countries, offering services to 160+ nations. The company provides microfluidics products through the Clinical Applications segment. It provides a wide range of microfluidics products, such as BIOFIRE Respiratory 2.1 (RP2.1) Panel, BIOFIRE SPOTFIRE respiratory solution, BIOFIRE respiratory panel, BIOFIRE SPOTFIRE respiratory panel mini, and BIOFIRE Spotfire systems, among others. In December 2024, bioMérieux (France) launched the BIOFIRE FILMARRAY Tropical Fever Panel (PCR test), which is a PCR test especially for malaria and dengue and provides results within one hour, thus allowing quick diagnosis.

Related Reports:

Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com